Healthcare & Insurance
Cannabis Leaf (PCFP) Completes Merger with Apotheca Biosciences – Company’s R & D Focuses on Opioid Crisis, a National Public Health Emergency
Saint Petersburg, FL, June 25, 2018 (GLOBE NEWSWIRE) -- Cannabis Leaf (OTC PINK: PCFP), a developer of cutting-edge medical products, nutraceuticals, formulation and cannabis delivery technologies for the healthcare and consumer care industry announces the completion of the merger with Apotheca
Monday, June 25, 2018
Mustang Bio Added to Russell 2000®, 3000® and Microcap® Indexes
NEW YORK, June 25, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology, today announced that the
Monday, June 25, 2018
PolarityTE Added to Russell 3000® and Russell 2000® Indexes
SALT LAKE CITY, June 25, 2018 (GLOBE NEWSWIRE) -- PolarityTE, Inc. (COOL), a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products for the fields of
Monday, June 25, 2018
ADMA Biologics Added to the Russell 3000 and Russell 2000 Indexes
RAMSEY, N.J. and BOCA RATON, Fla., June 25, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a vertically integrated commercial biopharmaceutical company that manufactures, markets and develops specialty plasma-based biologics for the prevention and treatment of certain infectious
Monday, June 25, 2018
Zafgen Set to Join Russell 3000® Index
BOSTON, June 25, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc., (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for patients affected by complex metabolic diseases, is set to join the Russell 3000® Index at the
Monday, June 25, 2018
Novo Nordisk A/S - Share repurchase programme
Bagsværd, Denmark, 25 June 2018 - On 4 May 2018, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR), also referred to as the Safe Harbour rules. This programme is part of the
Monday, June 25, 2018
Medtronic Receives CE Mark for MiniMed(TM) 670G Hybrid Closed Loop System
DUBLIN - June 25, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received CE (Conformité Européenne) Mark for the MiniMed(TM) 670G hybrid closed loop system - the first and only system to automate and personalize the delivery of basal insulin
Monday, June 25, 2018
Helius Medical Technologies, Inc. Joins Russell 3000® Index, Russell 2000® Index and Russell Microcap® Index
NEWTOWN, Pa., June 25, 2018 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, announced today that the Company has been added to the Russell 3000® Index, Russell 2000® Index
Monday, June 25, 2018
EyePoint Pharmaceuticals Announces Stockholder Approval of Second Tranche of Capital Financing
Expected closing of $25.5 million in capital to be used to accelerate EyePoint’s transformation into a commercial-stage specialty biopharmaceutical company Financing supports two near-term product launches anticipated in the first half of 2019 WATERTOWN, Mass., June 25, 2018 (GLOBE NEWSWIRE)
Monday, June 25, 2018
Unum Therapeutics Joins Russell 3000® Index
CAMBRIDGE, Mass., June 25, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (Nasdaq:UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies based on its novel, universal Antibody-Coupled T cell Receptor (ACTR) technology platform, today announced
Monday, June 25, 2018
Allergy Therapeutics announces publication of data demonstrating long-lasting efficacy of Pollinex Quattro Grass vaccine in Immunotherapy
Allergy Therapeutics plc (“Allergy Therapeutics” or the “Group”) Allergy Therapeutics announces publication of data demonstrating long-lasting efficacy of Pollinex Quattro Grass vaccine in Immunotherapy 25 June 2018 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial
Monday, June 25, 2018
BeyondSpring’s Principal Investigator in China for Chemotherapy-Induced Neutropenia Delivered Keynote Presentation at 12th Annual Chinese Symposium
China Chairman of NCCN Guidelines for Neutropenia Management, Dr. Yuankai Shi, Presented Positive Clinical Data Update on BeyondSpring’s Lead Asset, PlinabulinNEW YORK, June 25, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused
Monday, June 25, 2018
Easton Pharmaceuticals Strengthens its Board of Directors While Enhancing Existing Businesses and Moves Towards New Sectors and Industries
TORONTO, ON, June 25, 2018 (GLOBE NEWSWIRE) -- Easton Pharmaceuticals Inc. (OTC:EAPH) is pleased to announce the appointment of Mr. Panagis (“Panos”) Alivizatos, to its Board of Directors to enhance existing businesses and moves towards new sectors and industries. Mr. Alivizatos has over
Monday, June 25, 2018
International Stem Cell Corporation Publishes Advanced Stem Cell Therapy Methodology in Stem Cells and Development Journal
CARLSBAD, Calif., June 25, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced
Monday, June 25, 2018
REMINDER: Zafgen to Host ZGN-1061 Phase 2 Data Conference Call
BOSTON, June 25, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc., (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company using its proprietary knowledge of MetAP2 systems biology to help patients affected by a range of metabolic diseases, will host an investor conference call today, Monday, June 25,
Monday, June 25, 2018
Nancy J. Wysenski Joins Dova Pharmaceuticals’ Board of Directors
DURHAM, N.C., June 25, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced that Nancy J. Wysenski will join Dova’s Board of Directors effective immediately. In addition to her board responsibilities, Ms. Wysenki will also serve on both the Compensation Committee
Monday, June 25, 2018
Stemline Therapeutics Announces Completion of Rolling BLA Submission for ELZONRIS™ (tagraxofusp; SL-401) for the Treatment of BPDCN
NEW YORK, June 25, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that it has completed submission of a rolling Biologics License Application (BLA) to the U.S. Food and Drug
Monday, June 25, 2018
Pluristem and Fukushima University Report Positive Data: PLX-R18 Increases Survival Rates and Mitigates Severe Intestinal Damage after Acute
HAIFA, Israel, June 25, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today reported positive data from studies conducted in collaboration with Fukushima Medical University evaluating PLX-R18 cells as a
Monday, June 25, 2018
T2 Biosystems Added to the Russell 3000® Index
LEXINGTON, Mass., June 25, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced today that it has been added to the broad-market Russell 3000® Index. The addition
Monday, June 25, 2018
Kiniksa Pharmaceuticals, Ltd. Announces Exercise of the Underwriters’ Option to Purchase Additional Shares
HAMILTON, Bermuda, June 25, 2018 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq:KNSA) (“Kiniksa”), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical needs,
Monday, June 25, 2018
